...
首页> 外文期刊>Clinical Pharmacology and Therapeutics >Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia.
【24h】

Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia.

机译:安瓿分子对人产生的阿片类药物引起的通气抑制的选择性拮抗作用,而不会丧失阿片类药物的镇痛作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Ventilatory depression is a significant risk associated with the use of opioids. We assessed whether opioid-induced ventilatory depression can be selectively antagonized by an ampakine without reduction of analgesia. In 16 healthy men, after a single oral dose of 1,500 mg of the ampakine CX717, a target concentration of 100 ng/ml alfentanil decreased the respiratory frequency by only 2.9 +/- 33.4% as compared with 25.6 +/- 27.9% during placebo coadministration (P < 0.01).Blood oxygenation and the ventilatory response to hypercapnic challenge also showed significantly smaller decreases with CX717 than with placebo. In contrast, CX717 did not affect alfentanil-induced analgesia in either electrical or heat-based experimental models of pain. Both ventilatory depression and analgesia were reversed with 1.6 mg of naloxone. These results support the use of ampakines as selective antidotes in humans to counter opioid-induced ventilatory depression without affecting opioid-mediated analgesia.
机译:通气抑郁是与使用阿片类药物相关的重大风险。我们评估了阿片类药物是否可以选择性地拮抗阿片类药物引起的通气抑制而不降低镇痛作用。在16名健康男性中,单次口服1,500 mg的安瓿CX717后,目标浓度为100 ng / ml的阿芬太尼可使呼吸频率降低2.9 +/- 33.4%,而安慰剂为25.6 +/- 27.9%与安慰剂相比,CX717的血液氧合和对高碳酸血症激发的通气反应也显示出明显更小的下降。相反,在基于电或热的疼痛实验模型中,CX717均不影响阿芬太尼诱导的镇痛作用。通气镇静和镇痛均用1.6 mg纳洛酮逆转。这些结果支持在人类中使用安帕他酮作为选择性解毒剂来对抗阿片类药物引起的通气抑制而不影响阿片类药物介导的镇痛作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号